Brief: Moleculin Reports Independent Assessment Confirms No Cardiotoxicity Of Annamycin In 90 Subjects
13/01/2026 13:57
Jan 13 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN REPORTS INDEPENDENT ASSESSMENT CONFIRMS NO CARDIOTOXICITY OF ANNAMYCIN IN 90 SUBJECTS Source text: ID:nGNXc5PmNs Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM